Evaluation of the Safety of Relaxin in Preeclampsia

A Phase I Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Study to Evaluate the Safety of Recombinant Human Relaxin (rhRlx) in Subjects With Preeclampsia

The purpose of this study is to determine whether different doses of recombinant human relaxin is safe when given to women with severe preeclampsia

The effects of relaxin may be beneficial in the treatment of women with preeclampsia. This study will preliminarily evaluate the maternal, fetal and neonatal safety and tolerability of an IV infusion of relaxin compared with placebo given to women with severe preeclampsia.

Inclusion Criteria:

• Diagnosis of preeclampsia
• Hospital admission for expectant management

Exclusion Criteria:

• Eclampsia or history of seizures
• Vaginal bleeding
• Multifetal gestation
• Requirement for immediate delivery